Healthcare
Hisamitsu Pharmaceutical Co., Inc.(HTSUF)
Live Price
Offline$29.00
+0.00% today
Window Change
+0.21%
Window
Jun 25, 2025 โ May 8, 2026
- Market Cap
- $425.23B
- Revenue Growth
- +4.8%
- EPS Growth
- -8.9%
- Dividend Yield
- 2.0%
Coverage: 220 bars ยท Jun 25, 2025 โ May 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hisamitsu Pharmaceutical Co., Inc. (HTSUF) is a Healthcare stock with a market cap of $425.23B and listed on OTC. The stock last traded around $29.00 and up 0.2% across the available one-year price window (Jun 25, 2025 โ May 8, 2026). Baseline metrics include revenue growth of +4.8%, EPS growth of -8.9%, a dividend yield of 2.0%. What stands out right now is revenue +4.8%, EPS -8.9%, free cash flow +90.5% with operating margin 11.0% and ROIC 4.7%. The dividend is present but secondary, with a yield around 2.0%. Valuation is more restrained than many high-expectation growth names at P/E 22.3 and price/sales 2.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HTSUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.8% vs +7.6% peer median
Operating Margin
Below sector median
+11.0% vs +19.4% peer median
P/E
Below sector median
22.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Apr 13, 2026 with an EPS surprise of +102.8% and a revenue surprise of +30.2%.
The operating picture looks softer than before
Revenue is at +4.8% and EPS is at -8.9%, with operating margin around 11.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 9, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 13, 2026 | +102.8% | +0.0% | +0.0% | โ |
2026 Jan 6, 2026 | +18.1% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
HTSUF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HTSUF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HTSUF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HTSUF and SPY.
Company Overview
Hisamitsu Pharmaceutical Co., Inc.
Other OTC
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
- Leadership
- Kazuhide Nakatomi
- IPO Date
- Sep 23, 2010
- Employees
- 2.8k
- Street Address
- 408, Tashiro Daikan-machi
- Mailing
- Tosu, 841-0017
- Region
- Tosu, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 5293 1720
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 22.3
- EV/EBITDA
- 13.6
- Price/Sales
- 2.6
- Price/Book
- 1.5
Growth
- Revenue
- +4.8%
- EPS
- -8.9%
- Free Cash Flow
- +90.5%
Profitability
- Gross Margin
- 59.0%
- Operating Margin
- 11.0%
- Net Margin
- 11.8%
- ROE
- 7.0%
- ROIC
- 4.7%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 4.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.